Key Points
- Insider sale: Lorenz Muller sold 11,180 MIST shares on Jan. 26 at $1.93 for $21,577.40, cutting his stake by 5.16% to 205,406 shares, and he previously sold 53,566 shares on Dec. 15 at about $2.32.
- Mixed signals — clustered insider selling vs. product launch: Several executives (including CEO and COO) sold sizable holdings in Dec/Jan, intensifying negative sentiment, even as Milestone launched CARDAMYST in U.S. pharmacies and analysts remain mixed with a consensus "Moderate Buy" and an average $8.00 target.
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) insider Lorenz Muller sold 11,180 shares of the business's stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $1.93, for a total transaction of $21,577.40. Following the completion of the transaction, the insider directly owned 205,406 shares in the company, valued at $396,433.58. This trade represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Lorenz Muller also recently made the following trade(s):
- On Monday, December 15th, Lorenz Muller sold 53,566 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.32, for a total transaction of $124,273.12.
Milestone Pharmaceuticals Stock Performance
Shares of MIST stock opened at $1.94 on Thursday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The firm has a market cap of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a 52 week low of $0.63 and a 52 week high of $3.06. The firm's 50-day simple moving average is $2.23 and its two-hundred day simple moving average is $1.96.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. As a group, equities analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts have recently weighed in on MIST shares. Zacks Research upgraded Milestone Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday. HC Wainwright reiterated a "buy" rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, January 10th. Wells Fargo & Company upped their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an "overweight" rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Milestone Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $8.00.
View Our Latest Report on MIST
Hedge Funds Weigh In On Milestone Pharmaceuticals
A number of large investors have recently modified their holdings of the company. October Effect Ltd purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at approximately $105,000. SG Americas Securities LLC bought a new position in Milestone Pharmaceuticals in the 4th quarter valued at $197,000. Bay Rivers Group increased its holdings in shares of Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company's stock worth $58,000 after purchasing an additional 12,170 shares during the period. Millennium Management LLC purchased a new stake in shares of Milestone Pharmaceuticals in the third quarter worth $803,000. Finally, Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals in the third quarter worth $1,333,000. 86.18% of the stock is currently owned by institutional investors.
Milestone Pharmaceuticals News Summary
Here are the key news stories impacting Milestone Pharmaceuticals this week:
- Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
- Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from "Hold" to a "Strong Buy" (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
- Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock's average, which can mute a sustained bounce despite the product launch and upgrade.
- Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 - Joseph Oliveto
- Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 - David Bharucha SEC Form 4 - Lorenz Muller
- Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 - Jeffrey Edward Nelson
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company's research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone's pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.
Milestone's lead product candidates are delivered through inhalation or systemic administration, reflecting the company's commitment to optimizing therapeutic delivery directly to the lungs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
